Related Experiment Videos

Follow-up of 13 children with ureterosigmoidostomy

N J Bakker, K J van Damme, H J de Voogt

Birth Defects Original Article Series

|January 1, 1977

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Influence of a TiCl4 post-treatment on nanocrystalline TiO2 films in dye-sensitized solar cells.

The journal of physical chemistry. B·2006

Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.

European urology·1998

Short-term versus long-term addition of cyproterone acetate to buserelin therapy in comparison with orchidectomy in the treatment of metastatic prostate cancer. European Organization for Research and Treatment of Cancer--Genitourinary Group.

Cancer·1993

The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer.

The Prostate. Supplement·1992

The use of the LHRH-analogue Buserelin in the treatment of prostatic cancer. A 10-year review on 1522 patients treated in 119 centres on 4 continents.

Scandinavian journal of urology and nephrology. Supplementum·1991

Orchidectomy versus Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843.

The Journal of steroid biochemistry and molecular biology·1990

See all related articles